Evidence map›Paper›PMID 41721999›Full record

ReviewMolecular neurobiology2026

Advancements in Stem Cell Therapy for Managing Drug-Resistant Epilepsy.

Munerah Hamed

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Munerah HamedDepartment of Pathology, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia. mhhamed@uqu.edu.sa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is a common chronic disorder of the nervous system and it is typically characterized by repeated seizures that arise from dysregulated electrical activity in the brain. Even with widely used antiseizure drugs and the option of surgery in selected cases, roughly 20 to 30% of patients go on to develop drug-resistant epilepsy, with persistent seizures that are often accompanied by neuronal damage, oxidative stress, and signs of mitochondrial dysfunction. In this context, stem cell therapy has drawn strong interest as a possible therapeutic direction, largely because multiple stem cell populations carry regenerative and neuroprotective potential, including embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), neural stem cells (NSCs), induced pluripotent stem cells (iPSCs), and adipose-derived regenerative cells (ADRCs). Evidence from animal studies and early clinical work suggests that transplantation approaches might support restoration of inhibitory neuronal networks, tone down neuroinflammatory signaling, and promote broader repair processes within injured circuits, which together could contribute to more durable seizure control. This review highlights recent advances in stem cell-based strategies for epilepsy, with attention to proposed mechanisms, reported therapeutic effects, and the animal models most often used to test these ideas. We also consider related regenerative medicine approaches, such as neuroprotection and electrical stimulation, as adjunct options that may strengthen outcomes in drug-resistant epilepsy by targeting at least part of the underlying biology rather than only suppressing symptoms.

Indexed as

Drug Resistant EpilepsyStem Cell TransplantationAnimalsHumansRegenerative MedicineDrug-resistant epilepsyEpilepsyNeuroprotectionRegenerative medicineStem cell therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.